Protara Therapeutics (TARA) Stock Plunges After $75 Million Offering: Latest Trial Data, Analyst Targets and Outlook as of December 5, 2025
Protara Therapeutics, Inc. is ending the week in dramatic fashion. After a string of positive clinical updates for its lead cell therapy TARA‑002, the company has tapped equity markets with a $75 million public offering that has sent the stock down roughly 20% today, even as Wall Street price targets still imply several‑fold upside from current levels.GlobeNewswire+1
